fig6

Figure 6. IL-4 and IFNγ production in recirculating T cell subsets in canine glioma patients before and after treatment with M032. (A) Percentages of IFNγ, TNFα, IL-4, Granzyme B, and CD107 expression in CD4⁺ T cells after PMA ionomycin stimulation in healthy controls, canine glioma patients pre-M032 treatment, and at day 14 post-M032 treatment. Comparison between pre-M032 (black) and day 14 post-M032 (gray) revealed (B) no significant change in IFNγ and (C) a significant decrease in IL-4 post-M032 treatment. (D) Percentages of IFNγ, TNFα, IL-4, Granzyme B, and CD107B expression in CD8⁺ T lymphocytes after PMA ionomycin stimulation in healthy controls, pre-M032 treatment canine glioma patients and day 14 post-M032 treatment patients. Comparison between pre-M032 (black) and day 14-post M032 (gray) revealed a significant (E) decrease in IL-4 and (F) increase in IFNγ production at 14 days after treatment. Statistical significance (B-E) was evaluated using an unpaired student’s t test (Welch’s correction for unequal variance). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.